128
Participants
Start Date
June 30, 2010
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
Active laser photocoagulation
Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
Sham injections
Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Ranibizumab 0.5 mg
Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Novartis Investigative Site, Aschaffenburg
Novartis Investigative Site, Berlin
Novartis Investigative Site, Bonn
Novartis Investigative Site, Bremen
Novartis Investigative Site, Chemnitz
Novartis Investigative Site, Cologne
Novartis Investigative Site, Darmstadt
Novartis Investigative Site, Dessau
Novartis Investigative Site, Dortmund
Novartis Investigative Site, Dresden
Novartis Investigative Site, Eichstätt
Novartis Investigative Site, Essen
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Giessen
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Karlsruhe
Novartis Investigative Site, Kiel
Novartis Investigative Site, Landshut
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Marburg
Novartis Investigative Site, Mühlheim
Novartis Investigative Site, München
Novartis Investigative Site, Münster
Novartis Investigative Site, Nuremberg
Novartis Investigative Site, Postdam
Novartis Investigative Site, Recklinghausen
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Rosenheim
Novartis Investigative Site, Siegburg
Novartis Investigative Site, Stuttgart
Novartis Investigative Site, Ulm
Novartis Investigative Site, Würzburg
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY